ES2136065T3 - Regulacion de la produccion de inmunoglobulinas por la interleucina-9. - Google Patents

Regulacion de la produccion de inmunoglobulinas por la interleucina-9.

Info

Publication number
ES2136065T3
ES2136065T3 ES91918691T ES91918691T ES2136065T3 ES 2136065 T3 ES2136065 T3 ES 2136065T3 ES 91918691 T ES91918691 T ES 91918691T ES 91918691 T ES91918691 T ES 91918691T ES 2136065 T3 ES2136065 T3 ES 2136065T3
Authority
ES
Spain
Prior art keywords
interleukin
production
regulation
immunoglobulin production
ige
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91918691T
Other languages
English (en)
Inventor
Bernard Dugas
Catherine Druez
Pierre Braquet
Jean-Michel Inst Mencia-Huerta
Catherine Uyttenhove
Jean-Christophe Av Hip Renauld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Cancer Research
Ipsen Pharma SAS
Original Assignee
Ludwig Cancer Research
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Cancer Research, Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Ludwig Cancer Research
Application granted granted Critical
Publication of ES2136065T3 publication Critical patent/ES2136065T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2033—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transceivers (AREA)
  • Mobile Radio Communication Systems (AREA)

Abstract

SE DESCRIBE UN METODO PARA LA PRODUCCION DE INHIBICION DE IGE Y UN METODO PARA LA PRODUCCION DE INCREMENTO DE IGG. LOS METODOS ESTAN RELACIONADOS AL PAPEL DEL INTERLEUQUIN PRODUCCION DE ANTICUERPOS. DE FORMA ESPECIFICA, LA PRODUCCION DE IGG ESTA POTENCIADA MEDIANTE LA ADMINISTRACION O A UN SUJETO O A UN CULTIVO CELULAR DE UNA COMBINACION DE INTERLEUQUIN E INTERLEUQUIN LA ADMINISTRACION DE UNA CANTIDAD DE INHIBIDOR INTERLEIQUIN 9 AL SUJETO.
ES91918691T 1990-10-05 1991-10-01 Regulacion de la produccion de inmunoglobulinas por la interleucina-9. Expired - Lifetime ES2136065T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/593,238 US5132109A (en) 1990-10-05 1990-10-05 Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof

Publications (1)

Publication Number Publication Date
ES2136065T3 true ES2136065T3 (es) 1999-11-16

Family

ID=24373963

Family Applications (2)

Application Number Title Priority Date Filing Date
ES91918691T Expired - Lifetime ES2136065T3 (es) 1990-10-05 1991-10-01 Regulacion de la produccion de inmunoglobulinas por la interleucina-9.
ES98200841T Expired - Lifetime ES2194273T3 (es) 1990-10-05 1991-10-01 Regulacion de la produccion de inmunoglobulinas por la interleucina-9.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES98200841T Expired - Lifetime ES2194273T3 (es) 1990-10-05 1991-10-01 Regulacion de la produccion de inmunoglobulinas por la interleucina-9.

Country Status (11)

Country Link
US (1) US5132109A (es)
EP (2) EP0903150B1 (es)
JP (2) JP3205754B2 (es)
AT (2) ATE234632T1 (es)
AU (2) AU646509B2 (es)
CA (1) CA2093434C (es)
DE (2) DE69133225T2 (es)
DK (2) DK0903150T3 (es)
ES (2) ES2136065T3 (es)
GR (1) GR3031518T3 (es)
WO (1) WO1992005698A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018047A1 (en) * 1992-03-09 1993-09-16 Ludwig Institute For Cancer Research Nucleic acid sequences coding for or complementary to nucleic acid sequences coding for interleukin 9 receptor
DE4322330A1 (de) 1992-08-31 1994-03-03 Behringwerke Ag Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
US6911887B1 (en) 1994-09-12 2005-06-28 Matsushita Electric Industrial Co., Ltd. Inductor and method for producing the same
CA2666298A1 (en) * 1995-08-24 1997-03-06 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
US5908839A (en) * 1995-08-24 1999-06-01 Magainin Pharmaceuticals, Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
AU2007202406B2 (en) * 1995-08-24 2010-08-12 Ligand Pharmaceuticals Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9
WO1998024904A2 (en) * 1996-12-02 1998-06-11 Magainin Pharmaceuticals Inc. Il-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
CA2689842A1 (en) * 1996-12-02 1998-06-11 Genaera Corporation Il-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
ATE540695T1 (de) * 2001-06-08 2012-01-15 Genaera Corp Verfahren zur modulation von il-13
JP4270974B2 (ja) 2003-08-04 2009-06-03 本田技研工業株式会社 車両における燃料タンクの配置構造
US20100219541A1 (en) 2007-09-28 2010-09-02 Konica Minolta Opto, Inc. Method for manufacturing optical device
JP5440492B2 (ja) 2008-03-19 2014-03-12 コニカミノルタ株式会社 ウエハレンズの製造方法
EP2266789A4 (en) 2008-03-19 2013-10-23 Konica Minolta Opto Inc PROCESS FOR PRODUCING MOLDED BODY OR THIN LENS
WO2011136138A1 (ja) 2010-04-27 2011-11-03 コニカミノルタオプト株式会社 撮像用レンズ、ウエハレンズ、ウエハレンズ積層体、撮像用レンズの製造方法、撮像用レンズの中間物、撮像用レンズの中間物の製造方法
US9828087B2 (en) * 2016-01-27 2017-11-28 Honeywell International Inc. Systems and methods for ground effect ceiling limit display

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US511951A (en) * 1894-01-02 Chusetts
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
US4946945A (en) * 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5208218A (en) * 1988-09-19 1993-05-04 Ludwig Institute For Cancer Research T cell growth factor glycoproteins
US5580753A (en) * 1989-05-23 1996-12-03 Ludwig Institute For Cancer Research DNA encoding the human cytokine, interleukin-9
AU7552691A (en) * 1990-03-23 1991-10-21 GSF-Institut Fur Experimentalle Hamatologie Method for enhanced growth and proliferation of mast cells

Also Published As

Publication number Publication date
JP3205754B2 (ja) 2001-09-04
DE69131450D1 (de) 1999-08-19
EP0553198A1 (en) 1993-08-04
DE69133225T2 (de) 2004-02-19
WO1992005698A1 (en) 1992-04-16
AU8760791A (en) 1992-04-28
EP0903150A1 (en) 1999-03-24
DE69133225D1 (de) 2003-04-24
AU646509B2 (en) 1994-02-24
DE69131450T2 (de) 2000-03-30
DK0903150T3 (da) 2003-07-21
CA2093434A1 (en) 1992-04-06
JP2001253835A (ja) 2001-09-18
AU656493B2 (en) 1995-02-02
US5132109A (en) 1992-07-21
JPH06502404A (ja) 1994-03-17
AU5243493A (en) 1994-02-17
EP0553198A4 (en) 1994-08-17
GR3031518T3 (en) 2000-01-31
CA2093434C (en) 1999-08-10
ATE182079T1 (de) 1999-07-15
EP0903150B1 (en) 2003-03-19
ES2194273T3 (es) 2003-11-16
ATE234632T1 (de) 2003-04-15
DK0553198T3 (da) 1999-12-27
EP0553198B1 (en) 1999-07-14

Similar Documents

Publication Publication Date Title
AU656493B2 (en) Regulation of immunoglobin production by interleukin-4 and interleukin-9
DK0497706T3 (da) Termoformbar komposition, fremgangsmåde til fremstilling heraf samt anvendelse heraf med henblik på at opnå termoformede emner
DK450183D0 (da) Humane monoklone antistoffer mod et bakterietoksin samt disses fremstilling, kontinuerlige cellelinier, som producerer antitoksinantistoffer, samt antistoffernes anvendelser
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
EP0216454A3 (en) Method of promoting animal growth
FI850778A7 (fi) Menetelmä NO x-pitoisuuden alentamiseksi pyörrekerrospolttolaitteissa.
FI903827A0 (fi) Foerfarande foer reducering av immunoglobulin e-responser.
FI870502L (fi) Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja
NO172596C (no) Apolipoprotein b-spesifikke monoklonale antistoffer produsert av to nye hybridomer, anvendelse av disse og diagnostiske systemer inneholdende disse
EP0339163A3 (en) Monoclonal antibodies specific for hiv and hybridomas for their production
NL940019I1 (nl) Remming van het infecterende karakter in vitro en het cytopatische effect van htlv-iii/lav door 2',3'-didesoxycytidine
DE59309740D1 (de) Lyopilisierte, wirkstoffhaltige emulsion
FI900783A0 (fi) Anticancer-proteinfoerening.
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
IT8420610A1 (it) "Procedimento per migliorare la crescita delle piante mediante illuminazione intermittente"
ATE62896T1 (de) Vorrichtung zur anaeroben behandlung von biomasse.
ATE41927T1 (de) Phenylalkylamine - bioregulatoren.
ES536028A0 (es) Un procedimiento para producir interferon inmune humano recombinante intacto
DE69312391D1 (de) Synthetische Lipid-A Clykoconjugate-Antigene und deren Verwendung in Impfstoffen
DE69124317D1 (de) Monoklonale Antikörper gegen Leptosphaeria
IT1229123B (it) Tracciante per prodotti petroliferi
GB8811342D0 (en) Expression of antibody heavy & light chain variable domains as active hetero-dimer in myeloma cells
ATE26411T1 (de) Verfahren fuer die reduzierung des so2- und/oder nox-gehaltes in rauchgas.
SU1692146A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus l. - продуцент моноклональных антител к 146 s-компоненту вируса ящура o
ATE31623T1 (de) Injizierbare zusammensetzungen von bbm-928a.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 553198

Country of ref document: ES